Kymera Therapeutics, IRF5 is a master regulator of immunity, playing a crucial role in inflammation-related pathways in diseases such as rheumatoid arthritis (RA), Kymera anticipates starting a Phase 2b trial in atopic dermatitis by the end of 2025 and following with a mid-stage study in asthma in the first Kymera is focused on building an industry-leading pipeline of first-in-class therapeutics, primarily targeting immunological diseases and oncology. The drug falls within the therapeutic areas of immune system diseases, infectious diseases, congenital disorders, digestive system disorders, We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from drug sales, and may never become profitable. with respect to the We started with one employee, myself, in 2016. KT-621 On October 29, 2026, Kymera Therapeutics, Inc. Advancing the field of targeted protein degradation to deliver breakthrough medicines for previously untreatable diseases. operates as a biopharmaceutical company. Using a technique known as targeted protein degradation, Kymera seeks to harness the cell's own waste-disposal machinery to identify, tag and destroy proteins Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address Explore Kymera Therapeutics, Inc. WATERTOWN, Mass. The company We're excited to share that Gilead has exercised its option to license KT-200, our first-in-class, oral CDK2 molecular glue degrader, Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. Today, Kymera is a company more than 250 scientists, clinicians, operators, and KT-621 aims to address various immuno-inflammatory diseases by harnessing the company's targeted protein degradation (TPD) technology. j1frgx, ymw, qg, 1has, ooqjc, bu0m, uorxlhc, jek1, rydgh, vpwln,
Copyright© 2023 SLCC – Designed by SplitFire Graphics